Criteria for choosing anticoagulant therapy in COVID19 patients

Main Article Content

Seyed Pouriya Hosseini Mehr
Yuliia Dzekunova
Valentyn Smorzhevskyi


Objective: While COVID-19 continues to circulate around the world, there are still many uncertainties on how to treat patients infected with the potentially deadly virus and, more importantly, for how long!

COVID-19 causes many different symptoms, among which coagulopathy seems to play an essential role in the survival prognosis of patients. While WHO recommends thromboprophylaxis in all admitted covid patients, it is still not routinely used in many medical centers worldwide. It is also worth mentioning that there is no animosity on the anticoagulant agents' choice or the duration they should be prescribed. Recent data suggest that it is wise to prescribe a prophylactic dose of anticoagulant for a minimum of 3 months post-discharge to minimize the risk of thrombosis in COVID-19 patients.


Download data is not yet available.

Article Details

How to Cite
Hosseini Mehr, S. P., Dzekunova, Y., & Smorzhevskyi, V. (2022). Criteria for choosing anticoagulant therapy in COVID19 patients. Medical Science and Discovery, 9(10), 555–557.
Review Article
Received 2022-09-29
Accepted 2022-10-21
Published 2022-10-21


WHO recommends follow-up care, low-dose anticoagulants for COVID-19 patients [Internet]. [cited 2021 Apr 9]. Available from:

Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020 May 21;1–10. DOI:

Kaptein FHJ, Stals MAM, Huisman MV, Klok FA. Prophylaxis and treatment of COVID-19 related venous thromboembolism. Postgrad Med. :1–9.

Garcia-Olivé I, Sintes H, Radua J, Abad Capa J, Rosell A. D-dimer in patients infected with COVID-19 and suspected pulmonary embolism. Respir Med. 2020 Aug;169:106023. DOI:

Ataallah B, Sharma A, Tamanna S, Ng J, Haggerty G. Major Thrombotic Event Despite Anticoagulation in a Patient With COVID-19. Cureus [Internet]. 12(6). Available from:

COVID-19 and Coagulopathy - [Internet]. [cited 2021 Apr 9]. Available from:

Heparin and low-molecular-weight heparin - PubMed [Internet]. [cited 2021 Jan 24]. Available from:

A L, Da G, Gh L, M C. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis [Internet]. Thrombosis research. 2019 [cited 2021 Apr 9]. Available from:

Kustos SA, Fasinu PS. Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update. Medicines [Internet]. 2019 Oct 15;6(4). Available from: DOI:

Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020 Oct;194:101–15. DOI:

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study [Internet]. [cited 2020 Oct 15]. Available from:

E Y. The anti-inflammatory effects of heparin and related compounds [Internet]. Thrombosis research. 2008 [cited 2021 Jan 24]. Available from:

H K, T N, I M. Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation [Internet]. Heart and vessels. 2017 [cited 2021 Jan 25]. Available from:

Nakase T, Moroi J, Ishikawa T. Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients. Clin Transl Med [Internet]. 2018 Jan 12;7. Available from: DOI:

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury - Full Text View - [Internet]. [cited 2021 Jan 24]. Available from:

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 May 4;1–10. DOI:

Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013 Dec 24;8:49–65. DOI:

Szolnoky G. Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications. Dermatol Ther. n/a(n/a):e14437.